WCM
ENTA icon

Wedge Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Wedge Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,881
Closed -$245K – 539
2020
Q2 		$245K Sell
4,881
-1,450
-23% -$75K ﹤0.01% 446
2020
Q1 		$326K Buy
6,331
+809
+15% +$43.1K 0.01% 390
2019
Q4 		$341K Buy
5,522
+563
+11% +$34.9K ﹤0.01% 451
2019
Q3 		$298K Buy
+4,959
New +$368K ﹤0.01% 486

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wedge Capital Management's ENTA Position: Q3 2020 in Review

Wedge Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 4,881 shares — an estimated $245K sold.

Wedge Capital Management first reported a position in ENTA in Q3 2019 and held it in 4 quarters. The position peaked at $341K in Q4 2019. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

  • Wedge Capital Management reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Wedge Capital Management sold 4,881 Enanta Pharmaceuticals shares in Q3 2020, an estimated $245K.
  • Wedge Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Wedge Capital Management's Enanta Pharmaceuticals position peaked at $341K in Q4 2019.
  • 172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on Wedge Capital Management's 13F filing for Q3 2020, filed 8 Oct 2020.